Skip to main content

letter

. 1987 Aug;56(2):241–242. doi: 10.1038/bjc.1987.182

Do phenothiazines contribute to tumour regressions in lymphokine-activated killer cell/interleukin-2 treatments of renal cell cancer?

PMCID: PMC2002135 PMID: 3499164

241

Images in this article

Figure 1
on p.241

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

BELKIN M., HARDY W. G. Effect of reserpine and chlorpromazine on sarcoma 37. Science. 1957 Feb 8;125(3241):233–234. doi: 10.1126/science.125.3241.233. [DOI] [PubMed] [Google Scholar]
Fairchild R. G., Greenberg D., Watts K. P., Packer S., Atkins H. L., Som P., Hannon S. J., Brill A. B., Fand I., McNally W. P. Chlorpromazine distribution in hamsters and mice bearing transplantable melanoma. Cancer Res. 1982 Feb;42(2):556–562. [PubMed] [Google Scholar]
Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
Simpson G. M., Cooper T. B., Bark N., Sud I., Lee J. H. Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Arch Gen Psychiatry. 1980 Feb;37(2):205–208. doi: 10.1001/archpsyc.1980.01780150095010. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES